These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 30859374)
41. [Relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia responding to retreatment with inotuzumab ozogamicin]. Hashimoto H; Tamura Y; Yamada K; Katoh Y; Shimada T; Fujiwara R; Hanamoto H Rinsho Ketsueki; 2023; 64(8):746-750. PubMed ID: 37673626 [TBL] [Abstract][Full Text] [Related]
42. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Ogura M; Tobinai K; Hatake K; Uchida T; Kasai M; Oyama T; Suzuki T; Kobayashi Y; Watanabe T; Azuma T; Mori M; Terui Y; Yokoyama M; Mishima Y; Takahashi S; Ono C; Ohata J Cancer Sci; 2010 Aug; 101(8):1840-5. PubMed ID: 20491780 [TBL] [Abstract][Full Text] [Related]
43. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Aujla A; Aujla R; Liu D Biomark Res; 2019; 7():9. PubMed ID: 31011424 [TBL] [Abstract][Full Text] [Related]
45. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States. Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655 [TBL] [Abstract][Full Text] [Related]
46. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Jabbour E; Advani AS; Stelljes M; Stock W; Liedtke M; Gökbuget N; Martinelli G; O'Brien S; White JL; Wang T; Luisa Paccagnella M; Sleight B; Vandendries E; DeAngelo DJ; Kantarjian HM Am J Hematol; 2019 Apr; 94(4):408-416. PubMed ID: 30623490 [TBL] [Abstract][Full Text] [Related]
47. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Russell-Smith A; Murphy L; Nguyen A; Blauer-Peterson C; Terpenning M; Cao F; Li S; Bancroft T; Webb N; Dorman S; Shah R J Comp Eff Res; 2024 Feb; 13(2):e230142. PubMed ID: 38099517 [No Abstract] [Full Text] [Related]
48. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). Nakayama H; Ogawa C; Sekimizu M; Fujisaki H; Kosaka Y; Hashimoto H; Saito AM; Horibe K Int J Hematol; 2022 Oct; 116(4):612-621. PubMed ID: 35635686 [TBL] [Abstract][Full Text] [Related]
49. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. O'Brien MM; Ji L; Shah NN; Rheingold SR; Bhojwani D; Yuan CM; Xu X; Yi JS; Harris AC; Brown PA; Borowitz MJ; Militano O; Kairalla J; Devidas M; Raetz EA; Gore L; Loh ML J Clin Oncol; 2022 Mar; 40(9):956-967. PubMed ID: 35007127 [TBL] [Abstract][Full Text] [Related]
50. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Bhojwani D; Sposto R; Shah NN; Rodriguez V; Yuan C; Stetler-Stevenson M; O'Brien MM; McNeer JL; Quereshi A; Cabannes A; Schlegel P; Rossig C; Dalla-Pozza L; August K; Alexander S; Bourquin JP; Zwaan M; Raetz EA; Loh ML; Rheingold SR Leukemia; 2019 Apr; 33(4):884-892. PubMed ID: 30267011 [TBL] [Abstract][Full Text] [Related]
51. Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? Fingrut W; Davis W; McGinnis E; Dallas K; Ramadan K; Merkeley H; Leitch H; Abou Mourad Y; Cassaday RD; Ross C; Léger C Curr Oncol; 2020 Dec; 28(1):252-259. PubMed ID: 33704192 [TBL] [Abstract][Full Text] [Related]
52. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. George B; Kantarjian H; Jabbour E; Jain N Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449 [TBL] [Abstract][Full Text] [Related]
53. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions. Kantarjian HM; Boissel N; Papayannidis C; Luskin MR; Stelljes M; Advani AS; Jabbour EJ; Ribera JM; Marks DI Cancer; 2024 Nov; 130(21):3631-3646. PubMed ID: 39093036 [TBL] [Abstract][Full Text] [Related]
54. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Goy A; Forero A; Wagner-Johnston N; Christopher Ehmann W; Tsai M; Hatake K; Ananthakrishnan R; Volkert A; Vandendries E; Ogura M Br J Haematol; 2016 Aug; 174(4):571-81. PubMed ID: 27101934 [TBL] [Abstract][Full Text] [Related]
55. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Wagner-Johnston ND; Goy A; Rodriguez MA; Ehmann WC; Hamlin PA; Radford J; Thieblemont C; Suh C; Sweetenham J; Huang Y; Sullivan ST; Vandendries ER; Gisselbrecht C Leuk Lymphoma; 2015; 56(10):2863-9. PubMed ID: 25707288 [TBL] [Abstract][Full Text] [Related]
56. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004 [TBL] [Abstract][Full Text] [Related]
57. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Metheny LL; Sobecks R; Cho C; Fu P; Margevicius S; Wang J; Ciarrone L; Kopp S; Convents RD; Majhail N; Caimi PF; Otegbeye F; Cooper BW; Gallogly M; Malek E; Tomlinson B; Gerds AT; Hamilton B; Giralt S; Perales MA; de Lima M Blood Adv; 2024 Mar; 8(6):1384-1391. PubMed ID: 38170741 [TBL] [Abstract][Full Text] [Related]
58. Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia. Fischer D; Toenges R; Kiil K; Michalik S; Thalhammer A; Bug G; Gökbuget N; Lang F Ann Hematol; 2024 Feb; 103(2):489-498. PubMed ID: 37999763 [TBL] [Abstract][Full Text] [Related]
59. Sequential Therapy of Inotuzumab Ozogamicin and Blinatumomab as a Bridge-to Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Primary Refractory Acute Lymphoblastic Leukemia: A Case Report. Uchida E; Kurata T; Komori K; Kobayashi J; Kubota N; Sakashita K J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1228-e1230. PubMed ID: 34001796 [TBL] [Abstract][Full Text] [Related]